Tetraphase Pharma (TTPH) Tops Q4 EPS by 1c, Revenues Beat

Go back to Tetraphase Pharma (TTPH) Tops Q4 EPS by 1c, Revenues Beat

Tetraphase Pharmaceuticals (TTPH) PT Lowered to $4 at Piper Jaffray

March 15, 2019 3:39 AM EDT

Piper Jaffray analyst Edward Tenthoff lowered the price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $4.00 (from $6.00) while maintaining a Overweight rating.

... More